Navigation Links
ShangPharma Appoints Pharmaceutical Executive Dr. Mitchell Reff Chief Biologics Officer
Date:1/13/2014

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and technical expertise to discover and manufacture novel first-in-class and best-in-class biologic clinical development candidates to advance into the Pharmaceutical and Biotechnology company pipelines.

Dr. Reff received his Ph.D. in Medical Microbiology from Stanford University School of Medicine, and his Bachelor's degree in Chemistry from Massachusetts Institute of Technology. This was followed by a  Postdoctoral Fellowship at Harvard Medical School, and  a position at the National Cancer Institute. Dr. Reff then spent 8 years at SmithKline Laboratories working on gene expression in mammalian cells and protein engineering. After that, he joined Idec Pharmaceuticals as head of molecular biology in 1990. Dr. Reff had a distinguished 21 year career at Idec, and later at Biogen Idec. He was Vice President Discovery Oncology at Biogen Idec running multiple bicoastal oncology groups developing small molecule and recombinant protein therapeutic molecules for oncology and delivered 6 novel oncology drugs into clinical trials in 5 years.

In early 1990s, Dr. Reff was Project Leader targeting B cell lymphoma, building and expressing the chimeric mouse-human anti-CD20 monoclonal antibody (Rituxan), the first monoclonal antibody approved to treat a tumor. Dr. Reff led the efforts from discovery until Rituxan entered its pivotal clinical trial.

Dr. Reff is well-recognized in the pharmaceutical and research community having been listed as an inventor on approximately 29 patents and patent applications, and as an author in nearly 100 scientific publications and presentations.

About ShangPharma:

ShangPharma Corp is a leading contract research organization (CRO) providing a broad range of high-quality, integrated services across both drug discovery and drug development to help pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company today has a team of nearly 2,000 skilled scientists in 1 million square feet of state-of-the-art research facilities and office space. For more information, please visit: http://www.ShangPharma.com. ChemPartner is a wholly owned subsidiary of ShangPharma Corp and also the main brand of the group.


'/>"/>
SOURCE ShangPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Corporation Announces Completion of Merger
2. ShangPharma Corporation Announces Extraordinary General Meeting of Shareholders
3. ShangPharma Announces Third Quarter 2012 Results
4. ShangPharma to Report Third Quarter 2012 Financial Results on November 20, 2012
5. ShangPharma and Harbour Antibodies Announce Licensing Agreement
6. ShangPharma Announces Second Quarter 2012 Results
7. ShangPharma to Report Second Quarter 2012 Financial Results on August 20, 2012
8. ShangPharma Independent Committee Appoints Financial Advisor
9. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
10. ShangPharma Announces Receipt of "Going Private" Proposal at $8.50 to $9.50 Per ADS
11. ShangPharma Announces First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):